iShares
®
U.S.
Healthcare
ETF
Schedule
of
Investments
(unaudited)
July
31,
2024
(Percentages
shown
are
based
on
Net
Assets)
1
Schedule
of
Investments
Security
Shares
Value
a
Common
Stocks
Biotechnology
—
18
.6
%
AbbVie,
Inc.
............................
1,048,300
$
194,270,956
Alnylam
Pharmaceuticals,
Inc.
(a)
(b)
..............
74,685
17,734,700
Amgen,
Inc.
............................
317,308
105,495,391
Apellis
Pharmaceuticals,
Inc.
(a)
................
61,752
2,445,379
Biogen,
Inc.
(a)
...........................
86,157
18,368,672
BioMarin
Pharmaceutical,
Inc.
(a)
...............
111,660
9,416,288
Cerevel
Therapeutics
Holdings,
Inc.
(a)
...........
40,776
—
Exact
Sciences
Corp.
(a)
(b)
....................
107,876
4,927,776
Exelixis,
Inc.
(a)
...........................
169,256
3,969,053
Gilead
Sciences,
Inc.
......................
738,418
56,164,073
GRAIL,
Inc.
(a)
...........................
15,515
238,621
Incyte
Corp.
(a)
...........................
109,634
7,133,884
Ionis
Pharmaceuticals,
Inc.
(a)
(b)
................
85,756
4,241,492
Moderna,
Inc.
(a)
(b)
.........................
191,136
22,787,234
Natera,
Inc.
(a)
...........................
66,928
6,852,758
Neurocrine
Biosciences,
Inc.
(a)
................
58,974
8,348,949
Regeneron
Pharmaceuticals,
Inc.
(a)
.............
61,824
66,719,843
Roivant
Sciences,
Ltd.
(a)
....................
207,241
2,248,565
Sarepta
Therapeutics,
Inc.
(a)
(b)
................
53,552
7,617,236
Ultragenyx
Pharmaceutical,
Inc.
(a)
(b)
.............
51,601
2,323,077
United
Therapeutics
Corp.
(a)
..................
25,824
8,090,401
Vertex
Pharmaceuticals,
Inc.
(a)
................
152,983
75,836,733
Viking
Therapeutics,
Inc.
(a)
(b)
..................
62,186
3,544,602
628,775,683
a
Health
Care
Equipment
&
Supplies
—
19
.3
%
Abbott
Laboratories
.......................
1,023,421
108,421,221
Align
Technology,
Inc.
(a)
.....................
44,319
10,276,690
Baxter
International,
Inc.
....................
301,152
10,787,265
Becton
Dickinson
&
Co.
....................
171,032
41,228,974
Boston
Scientific
Corp.
(a)
....................
869,032
64,204,084
Cooper
Cos.,
Inc.
The
(a)
....................
115,425
10,772,615
Dentsply
Sirona,
Inc.
......................
122,383
3,321,475
Dexcom,
Inc.
(a)
..........................
233,962
15,867,303
Edwards
Lifesciences
Corp.
(a)
................
353,589
22,293,786
Enovis
Corp.
(a)
(b)
..........................
32,153
1,531,769
Envista
Holdings
Corp.
(a)
....................
101,607
1,734,431
GE
HealthCare
Technologies,
Inc.
.............
252,162
21,340,470
Globus
Medical,
Inc.
,
Class
A
(a)
...............
66,199
4,763,680
Hologic,
Inc.
(a)
...........................
136,665
11,153,231
IDEXX
Laboratories,
Inc.
(a)
...................
48,758
23,214,659
Inspire
Medical
Systems,
Inc.
(a)
(b)
..............
17,599
2,482,339
Insulet
Corp.
(a)
...........................
41,305
8,027,627
Intuitive
Surgical,
Inc.
(a)
.....................
209,024
92,934,161
Masimo
Corp.
(a)
(b)
.........................
25,503
2,728,311
Medtronic
PLC
..........................
786,487
63,170,636
Penumbra,
Inc.
(a)
.........................
21,803
3,643,063
QuidelOrtho
Corp.
(a)
.......................
31,412
1,234,177
ResMed,
Inc.
...........................
85,992
18,337,794
Solventum
Corp.
(a)
(b)
.......................
81,973
4,826,570
STERIS
PLC
............................
58,343
13,929,975
Stryker
Corp.
...........................
214,106
70,109,010
Teleflex,
Inc.
............................
27,848
6,152,180
Zimmer
Biomet
Holdings,
Inc.
................
120,913
13,463,662
651,951,158
a
Health
Care
Providers
&
Services
—
18
.6
%
Acadia
Healthcare
Co.,
Inc.
(a)
.................
53,804
3,489,189
Amedisys,
Inc.
(a)
.........................
18,892
1,852,361
Cardinal
Health,
Inc.
.......................
144,049
14,524,461
Centene
Corp.
(a)
.........................
315,510
24,269,029
Chemed
Corp.
...........................
8,778
5,004,864
Cigna
Group
(The)
........................
164,905
57,497,426
Security
Shares
Value
a
Health
Care
Providers
&
Services
(continued)
DaVita,
Inc.
(a)
............................
29,814
$
4,073,189
Elevance
Health,
Inc.
......................
137,573
73,192,963
Encompass
Health
Corp.
...................
58,521
5,438,942
HCA
Healthcare,
Inc.
......................
114,350
41,514,767
Henry
Schein,
Inc.
(a)
(b)
......................
75,540
5,434,348
Humana,
Inc.
...........................
71,306
25,784,963
Labcorp
Holdings,
Inc.
.....................
49,811
10,731,282
Molina
Healthcare,
Inc.
(a)
....................
34,343
11,720,236
Premier,
Inc.
,
Class
A
......................
69,615
1,460,523
Quest
Diagnostics,
Inc.
.....................
65,843
9,369,459
R1
RCM,
Inc.
(a)
..........................
92,754
1,194,671
Tenet
Healthcare
Corp.
(a)
....................
57,331
8,582,451
UnitedHealth
Group,
Inc.
....................
544,150
313,517,464
Universal
Health
Services,
Inc.
,
Class
B
.........
34,223
7,315,508
625,968,096
a
Health
Care
Technology
—
0
.6
%
Certara,
Inc.
(a)
(b)
..........................
70,621
1,102,394
Doximity,
Inc.
,
Class
A
(a)
(b)
...................
70,813
1,982,764
Veeva
Systems,
Inc.
,
Class
A
(a)
(b)
..............
87,233
16,742,629
19,827,787
a
Life
Sciences
Tools
&
Services
—
11
.5
%
10X
Genomics,
Inc.
,
Class
A
(a)
................
61,544
1,272,114
Agilent
Technologies,
Inc.
...................
173,237
24,495,712
Avantor,
Inc.
(a)
(b)
..........................
401,088
10,729,104
Azenta,
Inc.
(a)
(b)
..........................
32,278
2,010,597
Bio-Rad
Laboratories,
Inc.
,
Class
A
(a)
(b)
..........
11,413
3,861,703
Bio-Techne
Corp.
.........................
91,845
7,493,634
Bruker
Corp.
............................
61,995
4,247,277
Charles
River
Laboratories
International,
Inc.
(a)
(b)
....
30,204
7,372,796
Danaher
Corp.
..........................
391,684
108,527,803
Fortrea
Holdings,
Inc.
(a)
.....................
51,995
1,434,542
Illumina,
Inc.
(a)
...........................
94,205
11,549,533
IQVIA
Holdings,
Inc.
(a)
......................
106,602
26,248,610
Medpace
Holdings,
Inc.
(a)
...................
15,025
5,747,363
QIAGEN
NV
(a)
...........................
130,697
5,814,710
Repligen
Corp.
(a)
(b)
........................
32,947
5,513,680
Revvity,
Inc.
............................
72,970
9,165,762
Sotera
Health
Co.
(a)
(b)
......................
72,644
1,007,572
Thermo
Fisher
Scientific,
Inc.
.................
225,956
138,587,853
West
Pharmaceutical
Services,
Inc.
............
42,931
13,144,184
388,224,549
a
Pharmaceuticals
—
31
.1
%
Bristol-Myers
Squibb
Co.
....................
1,200,098
57,076,661
Catalent,
Inc.
(a)
..........................
107,016
6,350,330
Elanco
Animal
Health,
Inc.
(a)
..................
291,096
3,795,892
Eli
Lilly
&
Co.
...........................
503,320
404,805,176
Intra-Cellular
Therapies,
Inc.
(a)
................
60,860
4,790,899
Jazz
Pharmaceuticals
PLC
(a)
.................
35,776
3,944,304
Johnson
&
Johnson
.......................
1,427,342
225,305,935
Merck
&
Co.,
Inc.
.........................
1,500,355
169,735,161
Organon
&
Co.
..........................
150,627
3,292,706
Perrigo
Co.
PLC
.........................
80,129
2,265,247
Pfizer,
Inc.
.............................
3,354,607
102,449,698
Royalty
Pharma
PLC
,
Class
A
................
231,425
6,519,242
Viatris,
Inc.
.............................
704,982
8,502,083
Zoetis,
Inc.
,
Class
A
.......................
270,582
48,715,583
1,047,548,917
a
Total
Long-Term
Investments — 99.7%
(Cost:
$
3,014,293,009
)
...............................
3,362,296,190
Schedule
of
Investments
(unaudited)
(continued)
July
31,
2024
iShares
®
U.S.
Healthcare
ETF
(Percentages
shown
are
based
on
Net
Assets)
2
Derivative
Financial
Instruments
Outstanding
as
of
Period
End
Fair
Value
Hierarchy
as
of
Period
End
Various
inputs
are
used
in
determining
the
fair
value
of
financial
instruments.
These
inputs
to
valuation
techniques
are
categorized
into
a
fair
value
hierarchy
consisting
of
three
broad
levels
for
financial
reporting
purposes
as
follows:
Level
1
–
Unadjusted
price
quotations
in
active
markets/exchanges
for
identical
assets
or
liabilities
that
the
Fund
has
the
ability
to
access;
Level
2
–
Other
observable
inputs
(including,
but
not
limited
to,
quoted
prices
for
similar
assets
or
liabilities
in
markets
that
are
active,
quoted
prices
for
identical
or
similar
assets
or
liabilities
in
markets
that
are
not
active,
inputs
other
than
quoted
prices
that
are
observable
for
the
assets
or
liabilities
(such
as
interest
rates,
yield
curves,
volatilities,
prepayment
speeds,
loss
severities,
credit
risks
and
default
rates)
or
other
market–corroborated
inputs);
and
Level
3
–
Unobservable
inputs
based
on
the
best
information
available
in
the
circumstances,
to
the
extent
observable
inputs
are
not
available
(including
the
Valuation
Committee’s
assumptions
used
in
determining
the
fair
value
of
financial
instruments).
Security
Shares
Value
a
Short-Term
Securities
Money
Market
Funds
—
1
.3
%
BlackRock
Cash
Funds:
Institutional,
SL
Agency
Shares
,
5.45
%
(c)
(d)
(e)
......................
36,622,467
$
36,637,116
BlackRock
Cash
Funds:
Treasury,
SL
Agency
Shares
,
5.29
%
(c)
(d)
............................
5,579,025
5,579,025
a
Total
Short-Term
Securities — 1.3%
(Cost:
$
42,198,252
)
.................................
42,216,141
Total
Investments
—
101.0%
(Cost:
$
3,056,491,261
)
...............................
3,404,512,331
Liabilities
in
Excess
of
Other
Assets
—
(
1
.0
)
%
...............
(
32,953,692
)
Net
Assets
—
100.0%
.................................
$
3,371,558,639
(a)
Non-income
producing
security.
(b)
All
or
a
portion
of
this
security
is
on
loan.
(c)
Affiliate
of
the
Fund.
(d)
Annualized
7-day
yield
as
of
period
end.
(e)
All
or
a
portion
of
this
security
was
purchased
with
the
cash
collateral
from
loaned
securities.
Affiliates
Investments
in
issuers
considered
to
be
affiliate(s)
of
the
Fund
during
the
period
ended
July
31,
2024
for
purposes
of
Section
2(a)(3)
of
the
Investment
Company
Act
of
1940,
as
amended,
were
as
follows:
Affiliated
Issuer
Value
at
04/30/24
Purchases
at
Cost
Proceeds
from
Sale
Net
Realized
Gain
(Loss)
Change
in
Unrealized
Appreciation
(Depreciation)
Value
at
07/31/24
Shares
Held
at
07/31/24
Income
Capital
Gain
Distributions
from
Underlying
Funds
BlackRock
Cash
Funds:
Institutional,
SL
Agency
Shares
$
45,519,962
$
—
$
(
8,887,957
)
(a)
$
677
$
4,434
$
36,637,116
36,622,467
$
25,968
(b)
$
—
BlackRock
Cash
Funds:
Treasury,
SL
Agency
Shares
4,905,810
673,215
(a)
—
—
—
5,579,025
5,579,025
67,680
—
$
677
$
4,434
$
42,216,141
$
93,648
$
—
(a)
Represents
net
amount
purchased
(sold).
(b)
All
or
a
portion
represents
securities
lending
income
earned
from
the
reinvestment
of
cash
collateral
from
loaned
securities,
net
of
fees
and
collateral
investment
expenses,
and
other
payments
to
and
from
borrowers
of
securities.
Futures
Contracts
Description
Number
of
Contracts
Expiration
Date
Notional
Amount
(000)
Value/
Unrealized
Appreciation
(Depreciation)
Long
Contracts
E-Mini
Health
Care
Select
Sector
Index
.......................................................
67
09/20/24
$
10,194
$
145,809
iShares
®
U.S.
Healthcare
ETF
Schedule
of
Investments
(unaudited)
(continued)
July
31,
2024
3
Schedule
of
Investments
The
hierarchy
gives
the
highest
priority
to
unadjusted
quoted
prices
in
active
markets
for
identical
assets
or
liabilities
(Level
1
measurements)
and
the
lowest
priority
to
unobservable
inputs
(Level
3
measurements).
Accordingly,
the
degree
of
judgment
exercised
in
determining
fair
value
is
greatest
for
instruments
categorized
in
Level
3.
The
inputs
used
to
measure
fair
value
may
fall
into
different
levels
of
the
fair
value
hierarchy.
In
such
cases,
for
disclosure
purposes,
the
fair
value
hierarchy
classification
is
determined
based
on
the
lowest
level
input
that
is
significant
to
the
fair
value
measurement
in
its
entirety.
Investments
classified
within
Level
3
have
significant
unobservable
inputs
used
by
the
Valuation
Committee
in
determining
the
price
for
Fair
Valued
Investments.
Level
3
investments
include
equity
or
debt
issued
by
privately
held
companies
or
funds.
There
may
not
be
a
secondary
market,
and/or
there
are
a
limited
number
of
investors.
The
categorization
of
a
value
determined
for
financial
instruments
is
based
on
the
pricing
transparency
of
the
financial
instruments
and
is
not
necessarily
an
indication
of
the
risks
associated
with
investing
in
those
securities.
For
information
about
the
Fund’s
policy
regarding
valuation
of
financial
instruments,
refer
to
its
most
recent
financial
statements.
The
following
table
summarizes
the
Fund’s
financial
instruments
categorized
in
the
fair
value
hierarchy.
The
breakdown
of
the
Fund’s
financial
instruments
into
major
categories
is
disclosed
in
the
Schedule
of
Investments
above.
Level
1
Level
2
Level
3
Total
Assets
Investments
Long-Term
Investments
Common
Stocks
.........................................
$
3,362,296,190
$
—
$
—
$
3,362,296,190
Short-Term
Securities
Money
Market
Funds
......................................
42,216,141
—
—
42,216,141
$
3,404,512,331
$
—
$
—
$
3,404,512,331
Derivative
Financial
Instruments
(a)
Assets
Equity
Contracts
...........................................
$
145,809
$
—
$
—
$
145,809
a
(a)
Derivative
financial
instruments
are
futures
contracts.
Futures
contracts
are
valued
at
the
unrealized
appreciation
(depreciation)
on
the
instrument.
Fair
Value
Hierarchy
as
of
Period
End
(continued)